DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA489674
Title:
Targeting Therapy Resistant Tumor Vessels
Descriptive Note:
Final rept. 1 may 2006-31 Aug 2008
Corporate Author:
BURNHAM INST LA JOLLA CA
Report Date:
2008-08-01
Pagination or Media Count:
106.0
Abstract:
Anti-angiogenic therapy appears to eliminate immature blood vessels. This paradoxically leads to improvement of tumor blood supply, as the structure and function of mature tumor blood vessels, not specific for anti-angiogenic effect, is normalized. This is a serious limitation to the anti-angiogenic therapy. The goal of this project is to specifically distinguish these normalized therapy resistant vessels in breast cancer from those sensitive to anti-angiogenic treatment. To achieve this, we have developed tumor models for vascular normalization and are using in vivo phage display and isolation of peptides that specifically home to normalized tumor vessels resistant to anti-angiogenic therapy. The results obtained in this study will enable specific targeting and thus treatment of breast cancer vessels not responding to standard anti-angiogenic therapy.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE